Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy

XJ Liu, HC Zhao, SJ Hou, HJ Zhang, L Cheng… - Bioorganic …, 2023 - Elsevier
Vascular epidermal growth factor receptor-2 (VEGFR-2), as an important tyrosine
transmembrane protein, plays an important role in regulating endothelial cell proliferation …

Incorporating selenium into heterocycles and natural products─ from chemical properties to pharmacological activities

W Hou, H Xu - Journal of Medicinal Chemistry, 2022 - ACS Publications
Selenium (Se)-containing compounds have emerged as potential therapeutic agents for the
treatment of a range of diseases. Through tremendous effort, considerable knowledge has …

Contribution of Knoevenagel condensation products toward the development of anticancer agents: An updated review

R Tokala, D Bora, N Shankaraiah - ChemMedChem, 2022 - Wiley Online Library
Knoevenagel condensation is an entrenched, prevailing, prominent arsenal following
greener principles in the generation of α, β‐unsaturated ketones/carboxylic acids by …

Synthesis, molecular docking and DFT analysis of novel bis-Schiff base derivatives with thiobarbituric acid for α-glucosidase inhibition assessment

S Gul, F Jan, A Alam, A Shakoor, A Khan… - Scientific Reports, 2024 - nature.com
A library of novel bis-Schiff base derivatives based on thiobarbituric acid has been
effectively synthesized by multi-step reactions as part of our ongoing pursuit of novel anti …

Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors

HT Abdel-Mohsen, MA Omar, AM El Kerdawy… - European Journal of …, 2019 - Elsevier
In the present study, we report the discovery of a novel class of substituted 4-amino-2-
thiopyrimidines as antiangiogenic and antiproliferative agents. Structural hybridization …

An updated literature on BRAF inhibitors (2018–2023)

L Maji, G Teli, NM Raghavendra, S Sengupta, R Pal… - Molecular Diversity, 2024 - Springer
BRAF is the most common serine-threonine protein kinase and regulates signal transduction
from RAS to MEK inside the cell. The BRAF is a highly active isoform of RAF kinase. BRAF …

Treatment with a new barbituric acid derivative suppresses diet-induced metabolic dysfunction and non-alcoholic fatty liver disease in mice

FM Suk, FY Hsu, MH Hsu, WC Chiu, CC Fang, TL Chen… - Life Sciences, 2024 - Elsevier
Introduction Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver
disease, often accompanied by obesity, diabetes, and increased risks of depression and …

Treatment with a new barbituric acid derivative exerts antiproliferative and antimigratory effects against sorafenib resistance in hepatocellular carcinoma

YJ Liao, SM Hsu, CY Chien, YH Wang, MH Hsu… - Molecules, 2020 - mdpi.com
Hepatocellular carcinoma (HCC) is a common cause of cancer death worldwide. Sorafenib,
a multikinase inhibitor, is the first-line drug approved by the Food and Drug Administration …

Characterization of a novel barbituric acid and two thiobarbituric acid compounds for lung cancer treatment

SY Lee, B Slagle-Webb, AK Sharma… - Anticancer …, 2020 - ar.iiarjournals.org
Background/Aim: Previously, we reported the identification of a cytotoxic chemotype
compound CC-I (1a), a derivative of thiobarbituric acid. We also reported the anticancer …

[PDF][PDF] New thiobarbituric acid scaffold-based small molecules: Synthesis, cytotoxicity, 2D-QSAR, pharmacophore modelling and in-silico ADME screening

HSA El-Zahabi, MMA Khalifa, YMH Gado… - Eur. J. Pharm …, 2019 - academia.edu
A series of twenty five new thiobarbituric acid derivatives, viz. 3a-h, 4-7, 8a-c, 9, 10a-c, 11
and 12a-d, were designed and synthesized as potential cytotoxic agents. In-vitro screening …